Rolf P. Kreutz, MD
Associate Professor of Clinical Medicine
Dr. Kreutz is an Associate Professor of Clinical Medicine at the Indiana University School of Medicine, with a primary appointment in the Division of Cardiology and secondary appointment in the Division of Clinical Pharmacology. Dr. Kreutz currently is Chief of Cardiology and Medical Director of the cardiac catheterization laboratories at Eskenazi Health.
Dr. Kreutz received his medical degree from the University of Bern in Switzerland. He trained in Internal Medicine in Langenthal and the University of Zurich in Switzerland, and completed his residency training at the Johns Hopkins University/Sinai Program in Internal Medicine. Dr. Kreutz underwent subspecialty training in cardiovascular disease and interventional cardiology at Indiana University School of Medicine, where he also served as chief cardiology fellow.
He is a fellow of the American College of Cardiology, the American Heart Association, and the Society of Cardiovascular Angiography and Interventions. Dr. Kreutz is a member of the multidisciplinary structural heart team at IUH Methodist.
Methodist Hospital, Room KIC E400 1701 Senate Blvd.
Indianapolis, IN 46202-1239
University Hospital of Zurich, Switzerland
Johns Hopkins University/Sinai, Baltimore
My research interests are translational in nature, and focus on thrombosis, coronary artery disease, antiplatelet medications and ‘personalized medicine’. I am studying the effect of variations in the human genome on in- vivo drug response through pharmacogenetic analyses. I am interested in the effects of genomic or epigenetic variations on coronary thrombosis phenotypes, and use of ex-vivo thrombosis assays in risk stratification of patients with coronary artery disease.
Variations in Clinical Presentation, Risk Factors, Treatment, and Prognosis of Spontaneous Coronary Artery Dissection.
Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease.
Plasma and whole blood clot strength measured by thrombelastography in patients treated with clopidogrel during acute coronary syndromes.
Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response.
Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin.
Morbid obesity and metabolic syndrome in Ossabaw miniature swine are associated with increased platelet reactivity.
Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study.
American Board of Internal Medicine - Cardiovascular Disease
American Board of Internal Medicine - Interventional Cardiology
Coronary artery disease, valvular heart disease, cardiac catheterization, coronary intervention, and transcatheter aortic valve replacement (TAVR).